DSCC1在癌症患者生存预后、免疫微环境、免疫治疗和癌症药物治疗中的作用机制

doi:10.3969/j.issn.1671-7171.2024.12.004

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (3444 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the role of DNA replication and sister chromatid cohesion factor 1 (DSCC1) in survival prognosis, immune microenvironment, immunotherapy and cancer drug therapy in cancer patients.【Methods】Cancer Genome Atlas (TCGA), Genotypic Tissue Expression (GTEx), Human Protein Atlas (HPA), Tumor Immune Evaluation Resource 2.0 (TIMER2.0), single cell sequencing database (CancerSEA), Interactive gene/protein Search tool (STRING), GEO immunotherapy cohort and GDSC drug sensitive database agents were used to analyze the role of DSCC1 in survival prognosis, immune microenvironment, immunotherapy and cancer drug therapy in cancer patients.【Results】DSCC1 mRNA was highly expressed in 25 different types of cancer tissues and was associated with poor prognosis in patients with 11 types of cancer. The results of immunomicroenvironment research showed that the mRNA expression of DSCC1 was significantly correlated with a variety of immune cells, including various types of T helper cells, eosinophils, macrophages, mast cells, etc. Further studies predicted that patients with abnormal DSCC1 expression were expected to achieve better outcomes of immunotherapy. Enrichment analysis showed that the mRNA expression of DSCC1 was significantly correlated with cell cycle and p53 signaling pathway.【Conclusion】DSCC1 is a key molecule in the occurrence, development, diagnosis and treatment of cancer, and it affects the therapeutic effect of lung adenocarcinoma. DSCC1 plays an important role in a variety of cancers.

Key words： Neoplasms Prognosis DNA,Neoplasm Immunotherapy Drug Therapy

Received: 29 August 2024

PACS:

R73

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GONG Zhouping
	WANG Ningjun
	HUANG Liang
	et al

Cite this article:

GONG Zhouping,WANG Ningjun,HUANG Liang, et al. Analysis of DSCC1 in Survival Prognosis, Immune Microenvironment, Immunotherapy and Cancer Drug Therapy in Cancer Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(12): 1836-1840.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.12.004 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I12/1836

[1] SANTUCCI C, CARIOLI G, BERTUCCIO P, et al. Progress in cancer mortality, incidence, and survival: a global overview[J].Eur J Cancer Prev,2020,29(5):367-381.
[2] STENSTROM J, HEDENFALK I, HAGERLING C. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression[J].Breast Cancer Res,2021,23(1):27.
[3] XIE X W, WANG X Y, LIAO W J, et al. Effect of upregulated DNA replication and sister chromatid cohesion 1 expression on proliferation and prognosis in hepatocellular carcinoma[J].Chin Med J (Engl),2018,131(23):2827-2835.
[4] MERKLE C J, KARNITZ L M, HENRY-SANCHEZ J T, et al. Cloning and characterization of hCTF18, hCTF8, and hDCC1. Human homologs of a Saccharomyces cerevisiae complex involved in sister chromatid cohesion establishment[J].J Biol Chem,2003,278(32):30051-30056.
[5] BATRA R, HARDER N, GOGOLIN S, et al. Time-lapse imaging of neuroblastoma cells to determine cell fate upon gene knockdown[J].PLoS One,2012,7(12):e50988.
[6] YAMAGUCHI K, YAMAGUCHI R, TAKAHASHI N, et al. Overexpression of cohesion establishment factor DSCC1 through E2F in colorectal cancer[J].PLoS One,2014,9(1):e85750.
[7] JIN G C, WANG W S, CHENG P, et al. DNA replication and sister chromatid cohesion 1 promotes breast carcinoma progression by modulating the Wnt/β-catenin signaling and p53 protein[J].J Biosci,2020,45:127.
[8] WANG X, WU Y, LIU J L, et al. Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis[J].Toxicol Appl Pharmacol,2022,452:116169.
[9] KIM J T, CHO H J, PARK S Y, et al. DNA Replication and Sister Chromatid Cohesion 1 (DSCC1) of the replication factor complex CTF18-RFC is critical for colon cancer cell growth[J].J Cancer,2019,10(24):6142-6153.
[10] CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S A H, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J].Neoplasia,2017,19(8):649-658.
[11] SZKLARCZYK D, GABLE A L, NASTOU K C, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets[J].Nucleic Acids Res,2021,49(D1):D605-D612.
[12] TANG Z F, LI C W, KANG B X, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J].Nucleic Acids Res,2017,45(W1):W98-W102.
[13] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J].CA Cancer J Clin,2022,72(1):7-33.
[14] SOTAK M, SUMOVA A, PACHA J. Cross-talk between the circadian clock and the cell cycle in cancer[J].Ann Med,2014,46(4):221-232.
[15] SHAKYA R, TARULLI G A, SHENG L, et al. Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer[J].Oncogene,2017,36(31):4469-4480.
[16] HARJUNPAA H, LLORT ASENS M, GUENTHER C, et al. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment[J].Front Immunol,2019,10:1078.
[17] LIN W, ZHANG H L, NIU Z Y, et al. The disease stage-associated imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden[J].BMC Women's Health,2020,20(1):126.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(1): 131-134.